Column GROUP Iii, L.P. is Director & 10% Owner at NGM BIOPHARMACEUTICALS INC (NGM). They have made 8 open-market trades across 2 companies since 2019, most recently 2025-03-05.
CIK 0001668159
8 open-market purchases totalling $50.5M since 2019, never a sale. Across 8 scored buys the stock is up 41.4% at ninety days, and 36.1 points ahead of the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 38% | 38% | 75% |
| Avg Move | +2.2% | -1.8% | +41.4% |
| Alpha | +1.0% | -1.9% | +36.1% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TNYA | BUY | 2025-03-05 | 2025-03-07 | $0.70 | $25.0M | +31.3% | -9.7% | +1.6% |
| NGM | BUY | 2023-11-15 | 2023-11-17 | $0.69 | $16K | +11.5% | +17.8% | +122.4% |
| TNYA | BUY | 2023-03-10 | 2023-03-14 | $2.60 | $18K | -3.4% | +15.3% | +165.3% |
| NGM | BUY | 2023-01-20 | 2023-01-23 | $5.00 | $3K | -0.9% | -12.6% | -25.9% |
| TNYA | BUY | 2022-11-21 | 2022-11-23 | $2.60 | $25.0M | -13.6% | -30.6% | +20.4% |
| NGM | BUY | 2020-08-21 | 2020-08-25 | $17.96 | $331K | -6.6% | -17.1% | +24.4% |
| NGM | BUY | 2020-07-30 | 2020-08-03 | $17.99 | $13K | -5.7% | -7.9% | -2.3% |
| NGM | BUY | 2019-11-04 | 2019-11-06 | $11.99 | $101K | +5.3% | +30.6% | +25.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.